Skip to content
OpenCapital
Get started

Organon OGN Atozet — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Amgen logo
AMGNOtezla — Total revenues
$431M-1.4%
Incyte logo
INCYTABRECTA — Total revenues
$6M-6.3%
Amgen logo
AMGNTEPEZZA — Total revenues
$490M+28.6%
Gilead Sciences logo
GILDYeztugo — Total revenues
$166M—
Bristol-Myers Squibb logo
BMYSotyktu — Total Revenues
$69M+25.5%
Vertex Pharmaceuticals logo
VRTXALYFTREK — Product revenues, net
$424.4M+687%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%
Enterprise value$10.98B-26.4%
P/E6.6×+2.1×
P/S0.6×-0.8×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's atozet — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's atozet — revenue?
Organon (OGN) reported atozet — revenue of $85M in Q1 2026.
How has Organon's atozet — revenue changed year-over-year?
Organon's atozet — revenue increased by 10.4% year-over-year, from $77M to $85M.
What is the long-term trend for Organon's atozet — revenue?
Over 4 years (2021 to 2025), Organon's atozet — revenue has grown at a -8.2% compound annual growth rate (CAGR), from $458M to $325M.
What does atozet — revenue mean?
This metric represents the total gross revenue generated from the sale of the Atozet product line, a pharmaceutical therapy typically focused on lipid management. It serves as a key indicator of the product's market adoption, competitive positioning, and contribution to the company's established medicines portfolio. Tracking these revenues helps investors assess the lifecycle performance and demand trends for this specific therapeutic asset.